Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBAS499
- Development stage
- Preclinical
- Lead developer
- Pluvia Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PBAS499 is a preclinical-stage small molecule being developed by Pluvia Biotech for the treatment of Phenylketonuria (PKU) and Hyperphenylalaninemia (HPA). The drug acts by targeting Phenylalanine hydroxylase (PAH), the enzyme responsible for converting phenylalanine to tyrosine. Mutations in the PAH gene lead to the accumulation of phenylalanine, which is toxic to the brain. PBAS499 is designed to stabilize or enhance the activity of the PAH enzyme, thereby reducing blood phenylalanine levels and preventing the neurological complications associated with PKU.
- Other names
- PBAS499PBAS-499PBAS 499
02
Targets
PAH (Phenylalanine hydroxylase)
Beyond the preview
Go deeper on PBAS499.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBAS499.